Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• GNAS mutations activate G protein signaling, implicated in various cancers, but oncogenic mechanisms are unclear.
• Pancreatic ductal adenocarcinomas (PDAs) often harbor concurrent GNAS and KRAS mutations, originating from intraductal papillary mucinous neoplasms (IPMNs).

Purpose of the Study:

• To elucidate the oncogenic mechanisms of GNAS in pancreatic tumorigenesis.
• To investigate the cooperative roles of GNAS and KRAS mutations in IPMN initiation and PDA progression.

Main Methods:

• Development of genetically engineered mouse models (GEMMs) of pancreatic cancer.
• In vivo studies to assess tumor initiation, maintenance, and progression.
• Analysis of intracellular signaling pathways, including cAMP and protein kinase A.
• Metabolic profiling of lipid remodeling and fatty acid oxidation.

Main Results:

• Gnas^R201C cooperates with Kras^G12D to initiate IPMNs, which progress to invasive PDA upon Tp53 loss.
• Mutant GNAS is essential for tumor maintenance, mediated by protein kinase A-dependent suppression of salt-inducible kinases (Sik1-3).
• This pathway induces lipid remodeling and enhances fatty acid oxidation, revealing metabolic heterogeneity in Kras-mutant pancreatic neoplasms.

Conclusions:

• GNAS mutations drive pancreatic cancer through specific oncogenic mechanisms involving metabolic reprogramming.
• Salt-inducible kinases (SIKs) function as potent tumor suppressors in this context.
• Significant metabolic differences exist between Kras-mutant pancreatic cancers with and without GNAS mutations, suggesting context-dependent therapeutic strategies.